Cognition Therapeutics Secures Cash Through Q2 2027, Advances Zervimesine DLB Trials
Cognition Therapeutics reported a 2025 net loss of $23.5 million ($0.32 per share) versus $34 million ($0.86) in 2024 and confirmed cash runway through Q2 2027. The company is prioritizing zervimesine’s transition to tablet form and registrational trials for DLB psychosis, with FDA meetings pending and Phase 2 results underpinning its first-in-class potential.
1. Financial Results and Cash Runway
Cognition Therapeutics posted a 2025 net loss of $23.5 million or $0.32 per share, compared to $34 million or $0.86 in 2024, and expects existing cash to fund operations through the second quarter of 2027, underpinning stability for ongoing R&D.
2. Zervimesine Development Focus
The company has prioritized zervimesine for DLB psychosis based on promising Phase 2 data and sees first-in-class potential. It is not pursuing ocular indications at this time, has seen strong demand in its Expanded Access Program, and is collecting data on synergies with approved CNS and immunotherapies such as lecanemab and donanemab.
3. Clinical and Regulatory Path
Zervimesine’s transition from capsule to tablet form is underway with completion expected in 2026. FDA meetings to define registrational trial size, duration and primary endpoints have yet to occur, and the company plans to align with the EMA after U.S. agreement. The psychosis focus allows for smaller, faster trials with secondary cognitive measures.